News Release

June 9, 2023

Perseus Proteomics, Inc.
President & CEO: Takuya Yokokawa
e-mail: ir@ppmx.com

Announcement of Acceptance of Presentation of PPMX-T003 Phase I Interim Report at the 13th JSH International Symposium 2023

Perseus Proteomics Inc. is pleased to announce that the interim report presentation of phase I clinical trial of PPMX-T003, its anti-transferrin receptor antibody, among polycythemia vera ("PV") patients has been accepted at the 13th JSH International Symposium 2023 in Tsukuba.

Title: PHASE I SAFETY STUDY OF ANTI-TRANSFERRIN RECEPTOR ANTIBODY (PPMX-T003) IN PATIENTS WITH POLYCYTHEMIA VERA (INTERIM REPORT)

Author: Tomoki Ito/First Department of Internal Medicine, Kansai Medical University
Teruhito Takakuwa, Masayuki Hino, Hirohisa Nakamae/Department of Hematology, Osaka Metropolitan University
Keiko Katsumi, Tadashi Matsuura/Perseus Proteomics Inc.

Presenter: Teruhito Takakuwa

At the presentation, interim data of the phase I including the progress over the entire observation period of the patient No.3 will be presented in addition to the report at the 118th Japanese Society of Hematology Kinki Association Meeting on May 27, 2023.

END